Live Breaking News & Updates on Oncternal Therapeutics
Stay updated with breaking news from Oncternal therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Research analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock. Separately, HC Wainwright dropped their target price on shares of Oncternal Therapeutics from $28.00 to $19.00 and set a […] ....
StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Sunday morning. The firm issued a hold rating on the stock. Separately, HC Wainwright reduced their price objective on Oncternal Therapeutics from $28.00 to $19.00 and set a buy rating on the stock in a research note […] ....
The CAR T-cell therapy market for acute lymphoblastic leukemia is poised for substantial growth, driven by the anticipated launch of therapies such as OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22 ....
ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024 biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.